- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$0.43 beats by $0.26 | 1 | Seeking Alpha | ||
| Di | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress | 1 | GlobeNewswire (USA) | ||
| Di | BridgeBio Oncology Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Do | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.10. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 09.09. | Stifel cuts BridgeBio Oncology price target on pipeline shift | 2 | Investing.com | ||
| 08.09. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 14 | SEC Filings | ||
| 08.09. | BridgeBio Oncology Therapeutics, Inc.: BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers | 406 | GlobeNewswire (Europe) | BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive... ► Artikel lesen | |
| BRIDGEBIO ONCOLOGY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.08. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.08. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress | 756 | GlobeNewswire (Europe) | Continued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of... ► Artikel lesen | |
| 11.08. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.07. | JPMorgan startet Coverage für BridgeBio Oncology mit "Overweight"-Rating | 3 | Investing.com Deutsch | ||
| 08.07. | JPMorgan initiates BridgeBio Oncology stock with overweight rating | 2 | Investing.com | ||
| 22.06. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | Oppenheimer initiates BridgeBio Oncology stock rating at Outperform | 2 | Investing.com | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress | 607 | GlobeNewswire (Europe) | Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818... ► Artikel lesen | |
| 22.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman | 436 | GlobeNewswire (Europe) | Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development... ► Artikel lesen | |
| 20.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma | 353 | GlobeNewswire (Europe) | BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen BRIDGEBIO ONCOLOGY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRIDGEBIO ONCOLOGY THERAPEUTICS INC finden Sie auf Wallstreet Online.